Bracco Imaging has issued a statement on new results published in the journal Radiology which found that gadopiclenol (VUEWAY), which has half the dose (or the amount) of gadolinium found in other available gadolinium-based contrast agents, provides similar lesion visualization and contrast enhancement compared with gadobuterol (Gadavist).